Understanding Mania

the Spectrum of Mania
Clinical Description and Diagnosis
Epidemiology
Aetiology
Course and Outcome
Management and Treatment
References

Abstract: Mania, an abnormally elevated mood disorder normally found in the context of bipolar or manic-depressive disorder, comes at a high personal cost. Symptoms range from abrupt alertness and grandiose plans to financial excess, delusions, and embarrassing behavior. Manic behavioral patterns lack predictability, rendering treatment only partially  successful. Mild forms of mania benefit from lithium, while neuroleptics are faster acting in more severe cases. Alternative drugs are carbamazepine or valproate. Electroconvulsive treatment is indicated after routine drug therapy  fails.

 Mania is an abnormal condition of elevated mood which affects about 1% of the population, and which usually occurs in  association with episodes of depression to constitute bipolar disorder or manic-depressive illness. It is a disorder with considerable implications for personal and social functioning where impairments can be severe and long-lasting, even after sustained clinical recovery.1
 

The Spectrum of Mania

Manic symptoms cover a spectrum of severity from cyclothymia to severe delusional mania. Cyclothymia, which usually starts in adolescence or early adulthood, describes fluctuations of mood between mild elation and depression. Although mild elation of this type may be associated with enhanced personal and social functioning, cyclothymia can also lead to considerable social or  interpersonal difficulties because of its unpredictability. A proportion of cyclothymic individuals go on to develop mania. Bipolar 
disorder is characterised by clinically marked mood swings between mania and depression. The DSM classification further  differentiates between bipolar I (BPI) and bipolar II (BPII) disorders. Mania is characteristic of BPI, while mild mania or hypomania  (not requiring hopitalisation) is characteristic of BPII. Unipolar mania describes recurrent episodes of mania in the absence of depressive illness. It is uncommon and otherwise resembles bipolar disorder. Secondary or induced mania describes manic symptoms or syndromes that are seen in various organic conditions. Finally, there are conditions which lie between the schizophrenias and affective disorders, so-called schizo-affective disorders. When manic symptoms are the predominant mood component, these disorders tend to pursue a course similar to that of manic-depressive illness rather than schizophrenia.2 

Back to Top

Clinical Description and Diagnosis

An episode of mania may begin abruptly, over the space of a few hours or days, or gradually, over some weeks. The subjective experience of mania in its minor forms usually includes heightened feelings of well-being with increased alertness and drive, inflated self-esteem, and expansive sociability. In addition to a general elevation of mood, instability or lability is typical. Irritability may easily be evoked, and other mood states such as anxiety or sadness, fleetingly but intensely expressed, may become apparent. In mixed 
mood states (also referred to as dysphoric mania), pronounced symptoms of both depression and mania either coexist or alternate during different periods of the day. As mania deepens, overactivity and overtalkativeness become more obvious. Grandiose ideas and plans, and grandiose delusions may develop. Overspending or socially embarrassing behaviour can be a source of great distress to  the family and the recovering patient. Up to two-thirds of patients experience psychotic symptoms at some time. Delusions occur more commonly than hallucinations, but ideas of reference or even experiences of possession or control, may also be seen. In most  cases these symptoms are transient, their content reflects the underlying mood, and the diagnosis remains clear. 

 The differential diagnosis of mania includes schizophrenia, drug-induced states, and organic disorders. It is sometimes difficult to  distinguish between mania and schizophrenia, especially if psychotic symptoms are prominent, incongruent with the underlying mood, or persist after the overactivity subsides. Such diagnostic difficulties are commonly found in cases presenting in adolescence. When affective and schizophrenic symptoms are evenly balanced and prominent enough such that a diagnosis of each can be made 
independently, then the term schizo-affective disorder is used. Kraepelin’s original distinction between schizophrenic and affective diagnoses was founded on both cross-sectional data and longitudinal course, and the need to maintain this dual perspective remains. Quite frequently, it is only over a prolonged period of observation that the diagnosis can be established with reasonable certainty. Drug-induced states and organic conditions must also be included in the differential diagnosis. Steroids, stimulants, and  antidepressants are known to induce manic symptoms and a large variety of other drugs have al so been implicated. Secondary mania can occur due to a variety of neurological lesions and metabolic or other states affecting brain functioning. Although late-onset cases of mania do occur, the likelihood of organic causation should always be considered, especially in the absence of a past or a family history of affective disorder. Sometimes the delirium of severe mania can itself resemble that of an acute confusional state. Alcohol and other substance abuse are important co-morbid conditions, and their intake-often escalates during acute episodes of mania,  sometimes masking or clouding the presentation. 

Back to Top

Epidemiology

 The lifetime prevalence of mania (bipolar affective disorder) is approximately 1%. Onset is most common in late adolescence or early adulthood although new cases are seen in all decades. First occurrence in childhood or early adolescence is increasingly being recognised, when it is sometimes accompanied by hyperactivity disorders.3 A minority, about 10%, of people with major depression will subsequently develop mania, most within 5 years of onset. Prevalence rates do not differ between men and women. Rates may be raised among the unmarried and separated or divorced which may reflect the deleterious effect this disorder can have on relationships. Raised rates have been reported in urban dwellers and among the homeless.4 A number of studies have reported a raised prevalence in upper socio-economic groups although these findings may be due to diagnostic bias. A possibly related finding is the greater social and occupational attainment sometimes seen among the relatives of those with bipolar disorder. Seasonal effects on incidence have been reported, the most common being a spring-summer excess of elation. Secondary mania due to organic factors occurs sporadically and its overall incidence is unknown, but it is probably more common than believed and is possibly under-recognised. In general, drug-induced manic disturbances are more likely to occur in predisposed individuals (those with previous episodes of mania or depression or with a family history of mood disorders), while mania due to structural brain damage may show less association with prior vulnerability. 

Back to Top

Aetiology

Mania shows greater heritability than any of the other major disorders in psychiatry. Concordance rates for monozygotic twins are about 70% and the risk for mood disorders among first degree relatives is about 20%,5 depression being more frequently reported han mania. Earlier reports of genetic linkage have not been replicated in wider populations, although large-scale studies are underway. Disturbances in monoamine neurotransmitter function have been studied much less extensively in mania than in depression. 
 In recent years attention has shifted towards the study of intracellular modulatory functions such as signal transduction mechanisms  and second-messenger systems. Lithium may inhibit both the cAMP and phosphoinositol second-messenger generating systems, and also alter signal transduction through its effects on guanine nucleotide binding (G) proteins.6 This secondary regulation affects the functioning of multiple neurotransmitter systems, and may well provide hypotheses for elucidating neurochemical regulation of mood in addition to denoting possible molecular mechanisms underlying lithium’s therapeutic actions. Computed tomographic and magnetic resonance imaging (MRI) findings include ventricular enlargement and increased sulcal prominence which are not specific to mania but are also seen in schizophrenia.7 Additional MRI findings of increased subcortical hyperintensities point to the presence of focal abnormalities of white matter and have been reported among young as well as older patients.8 Their occurrence in younger individuals shows some correlation with increased cognitive impairment and with positive family history. Electroencephalogram abnormalities have been reported in substantial minorities and paroxysmal abnormalities have sometimes been reported in association with suicidal and other behavioural disturbance.9 While a number of studies have suggested a possible role for stressful life events in  recipitating mania, most have been retrospective and the evidence must be interpreted with caution. A considerable proportion of women with established bipolar disorder who have children will suffer a puerperal psychosis. For those with established bipolar disorder and a previous puerperal disturbance the risk for subsequent pregnancies rises to more than 50%.10 While metabolic and endocrine changes are likely to be of primary importance, it has also been suggested, somewhat speculatively, that sleep deprivation may underlie the often-noted manic response to such disparate events as childbirth, bereavement, and jet-lag associated with time-zone travel.11 Secondary mania has been observed in association with a variety of neurological conditions including multiple sclerosis, brain  tumours, epilepsy, and brain trauma, and also in association with metabolic and endocrinological disorders such as hyperadrenocorticalism and hyperthyroidism. Some studies have suggested that midline or right-sided lesions in particular may give rise to manic syndromes.12 Drugs commonly noted to induce mania include corticosteroids and androgenic steroids, L-dopa and antidepressants. 

Back to Top

Course and Outcome

Most manic episodes remit with treatment within a few months. However, the majority of patients will go on to have recurrences. Variability in outcome is considerable. While the length of episode does not show any consistent variation over time, some follow a pattern where the duration between the first few episodes seems to shorten progressively. Thereafter, it may level out and, later, may begin to lengthen again. In general, more depression and less mania is associated with advancing age. Chronicity, that is either 
unremitting illness or recovery of only a few weeks before the next episode, occurs in a small minority.13 Full occupational or social recovery lags behind clinical recovery, and many individuals show enduring difficulties in some areas of social adjustment.1 

 Predicting the course of the disorder is difficult. Probably the best indication of future trends is the pattern of episodes in the past.  Those with childhood or adolescent onset may follow a more severe course in early years but in the longer term often fare no  worse.14 A positive family history of mania is predictive of more manic recurrences over time.13 Women tend to experience more depressive and mixed mood states and, conversely, fewer elations than men, and mixed states are associated with poor response to treatment in the short term. Women are also about three times more likely than men to experience rapid cycling, arbitrarily defined as the occurrence of four or more episodes in a year. In addition to occurring more frequently in women, rapid cycling is also associated with antidepressant use and possibly with hypothyroidism, although the evidence for the latter is less clear-cut.15 While rapid cycling,  which occurs in up to 20% of cases, is predictive of a stormier course, it does not persist indefinitely but tends to be phasic over  time.16 The association of mania with childbirth has already been mentioned. The observation of mild hypomania (“the highs”) during  the first week postnatally has been associated with a higher risk of depression in subsequent months.17 

 The presence of comorbid illness can adversely affect the outlook for mania, being associated with  ncreased dysphoria and mixed mood states and with treatment resistance. Commonly occurring comorbid illnesses include alcoholism and substance abuse. The alcoholism that accompanies bipolar disorder may be qualitatively different to that seen in other populations and have a high rate of remission. In one series of cases where alcoholism preceded the onset of mania, subsequent abstinence was associated with a 
reduced frequency of manic-depressive recurrences.18 

The possibility of suicide should not be forgotten in the management of manic states. Although it is relatively uncommon in pure or uncomplicated mania, the expression of suicidal thoughts occurs in more than 50% of those with mixed mood states.19 Furthermore,  mania is often succeeded by depression, sometimes quite abruptly, and suicidal expression can be an important early emergent feature. Comorbidity, especially alcohol and drug abuse, increases risk of suicide considerably. 

 In BPII disorder, the degree of elation is mild and does not warrant admission to hospital. Because it is mild, it may not be spontaneously reported by the patient. It does however, mark a disorder which can sometimes be characterised by atypical and chronic depression with high levels of associated comobid disturbance and psychosocial impairment and which is often resistant to treatment.20 

Back to Top

Management and Treatment

Mild mania may be managed at out-patient clinics but it is important to realise that progression to more severe mania can occur quite rapidly and unexpectedly. Out-patient management should include frequent clinical monitoring and a careful evaluation of the patient’s support network. It is important to extend support to family members and to monitor their coping abilities. The possible consequences for both patient and family of disinhibited or socially embarrassing behaviour may dictate a prudent policy in relation to hospital admission. If admission is indicated tactful persuasion, perhaps with help from family members, may be enough to encourage the patient’s agreement. Often, however, the manic patient lacks sufficient insight and involuntary detention must be considered. 

 Milder cases of mania may respond well to lithium, either alone or with benzodiazepines. Lithium, which has fewer side effects than neuroleptics, may also help prevent subsequent depressive relapse, a fairly common occurrence. Doses sufficient to maintain 12-hour serum concentrations of 1.0-1.2 mmol/L are usually required and a delay of about 7-10 days before onset of action may be expected. Benzodiazepines may be added for sedation and to restore sleep. In more severe cases, lithium alone is impractical, and it 
 may than be combined with neuroleptics which have a faster onset of action. There is a trend towards lower doses and less frequent use of neuroleptics in mania because of tardive dyskinesia, neurotoxicity, neuroleptic malignant syndrome, and because of the possibility of cardiac conduction disturbances and sudden death with high doses.21 Some studies report adequate clinical response to moderately low-dose neuroleptic treatment (ie, haloperidol 10 mg/day or equivalent) rather than higher doses.22 Although lithium remains the treatment of choice in mania, carbamazepine or valproate are increasingly being used as alternatives or, with lithium, in place of neuroleptics. Although some reports have suggested that they may be of particular benefit in mixed-mood states and rapid-cycling disorder, situations where lithium does not appear to be highly effective, no firm conclusions can be drawn because of the paucity of adequate controlled trials.23 Treatment of acute mania with anticonvulsants, as with lithium, usually requires the addition of other more sedative medication. Open trials with other drugs, including calcium-channel blockers such as verapamil24 and new  anticonvulsants,25 suggest potential benefits from these agents. Electroconvulsive treatment continues to be a effective treatment with good response rates in those otherwise failing to respond to treatment and reported response rates of about 80% overall in mania.26 
Secondary mania is treated similarly. 

For prophylaxis, lithium is again the drug of first choice. The decision when to initiate lithium prophylaxis depends on the likelihood of early recurrence. Generally, if episodes recur every year or two then prophylactic treatment should be considered, but if bipolar disorder presents with a manic episode in an adolescent or young adult it should probably be used from the outset. Increasing awareness of limitations to lithium’s effectiveness reflects less impressive responses noted from trials in the last two decades than 
earlier, and also a disparity between the results of case-control trials and follow-up studies. Possible explanations include that use of lithium has become more widespread and it may have been used for conditions other than bipolar disorders.27 The risk of rebound  mania after stopping lithium may be considerably higher than the natural risk.28 There is some evidence, too, that reintroduction of 
lithium after discontinuation fails to restore mood stability to the same degree.29 Finally, studies of alternate day dosing strategies would appear to indicate that even minor degrees of noncompliance carry an increased risk of relapse.30 If lithium must be discontinued (or the patient wishes to discontinue it), gradual reduction over a few weeks is associated with a considerably lower risk of relapse than abrupt discontinuation.31 Some studies have shown that elevated mortality rates in those with bipolar disorder, mainly  from suicide, can be reduced considerably among those on long-term lithium treatment.32 There is not enough evidence to advocate the more widespread use of anticonvuls ants as first-line agents in prophylaxis. They may be considered in cases of non-response or intolerance to lithium. Although most studies have shown little advantage from prophylaxis with neuroleptics, those who relapse 
frequently on mood stabilisers are often maintained on neuroleptics.33 

The psychological and social consequences of mania can be considerable. While mood-stabilizing drugs remain the primary focus of intervention, psychotherapy is an essential adjunctive treatment. Studies of psychosocial interventions have been few and lack sufficient rigour. However, tentative evidence suggests some success in reducing recurrence and future research should focus on more 
systematic evaluation of these adjunctive therapies.34 

Back to Top

References

  1. Coryell W, Scheftner W, Keller M, Endicott J, Master J, Klerman GL. The enduring social      consequences of mania and depression. Am J Psychiatry 1993; 150: 720-27.
  2. Coryell W, Keller M, Lavori P, Endicott J. Affective syndromes, psychotic features and prognosis. II Mania. Arch Gen Psychiatry 1990; 437: 658-64.
  3. Woznniak J, Biederman J, Mundy E, Mennin D, Faraone SV. A pilot family study of childhood-onset mania. J Am Acad Child Adolesc Psychiatry 1995; 34: 1577-83.
  4. Koegel P, Burman AM, Farr RK. The prevalence of specific psychiatiric disorders among homeless individuals in the inner city of Los Angeles. Arch Gen Psychiatry 1988; 45: 1085-92.
  5. McGuffin P, Katz R. Nature, nurture and affective disorder. In: Deakin JWF, ed. The biology of depression. London:  Gaskell, 1986: 26-51.
  6. Manji HK, Potter WZ, Lenox RH. Signal transduction pathways. Molecular targets for lithium’s actions. Arch Gen Psychiatry 1995; 52: 531-43.
  7. Elkis H, Friedman L, Wise A, Meltzer HY. Meta-analyses of studies of ventricular enlargement and cortical sulcal prominence in mood disorders. Arch Gen Psychiatry 1995; 52: 735-46.
  8. Dupont RM, Jernigan TL, Heindel W, et al. Magnetic resonance imaging and mood disorders. Localisation of white matter and other subcortical abnormalities. Arch Gen Psychiatry 1995; 52: 747-55.
  9. Struve FA, Saraf KR, Arko RS, Klein DF, Becka DR. Relationships between paroxysmal electroencephalographic dysrhythmia and suicide ideation and attempts in psychiatric patients. In Shagass C, Gershon S, Friedhoff AJ, eds. Psychopathology and brain dysfunction. New York: Raven Press, 1979: 199-221.
  10. Dean C, Williams RJ, Brockington IF. Is puerperal psychosis the same as bipolar manic-depressive disorder? A family study. Psychol Med 1989.: 19: 637-47.
  11. Wehr TA, Sack DA, Rosenthal NE. Sleep reduction as a final common pathway in the genesis of mania. Am J Psychiatry 1987; 144: 201-04.
  12.  Strakowski SM, McElroy SL, Keck PW Jr, West SA. The co-occurrence of mania with medical and other psychiatric disorders. Int J Psychiatry Med 1994; 24: 305-28.
  13. Winokur G, Coryell W, Akiskal HS, Endicott J, Keller M, Mueller T. Manic-depressive (bipolar) disorder: the course in light of a prospective ten-year follow-up of 131 patients. Acta Psychiatr Scand 1994; 89: 102-10.
  14. McGlashen T. Adolescent versus adult onset of mania. Am J Psychiatry, 1988; 145: 221-23.
  15. Leibenluft E. Women with bipolar illness: clinical and research issues. Am J Psychiatry, 1996; 153: 63-173.
  16. Coryell W, Endicott J, Keller M. Rapidly cycling affective disorder: demographics, diagnosis, family history and course. Arch Gen Psychiatry 1992; 49: 126-31.
  17. Glover V, Liddle P, Taylor A, Adoing D, Sandler M. Mild hypomania (the highs) can be a feature of the firstpost-partum week — association with later depression. Br J Psychiatry 1984; 164: 517-21.
  18. Winokur G, Coryell W, Akiskal HS, et al. Alcoholism in manic-depressive (bipolar) illness: familial illness, course of illness, and the primary-secondary distinction. Am J Psychiatry 1995; 152: 365-72.
  19. Dilsaver SC, Chen YW, Swann AC, Shoaib AM, Krajewski KJ. Suicidality in patients with pure and depressive mania. Am J Psychiatry 1994; 15: 1312-15.
  20. Simpson SG, Folstein SE, Meyers DA, McMahon FJ, Brusco DM, DePaulo Jr. Bipolar II: the most common bipolar phenotype? Am J Psychiatry 1993; 150: 901-03.
  21. Royal College of Psychiatrists. Consensus statement on the use of high dose antipsychotic medication. Council report CR26. London: Royal College of Psychiatrists, 1992.
  22. Rifkin A, Karajbi B, Doddi S, et al: Dose and blood levels of haloperidol in treatment of mania. Psychopharmacol Bull 1990; 76: 144-46.
  23. Post RM. Alternatives to lithium for bipolar affective illness. In: Tassman A, Kaufman C, Goldfinger S, eds. APA annual review 9. Washington DC: APA Press, 1990: 170-202.
  24. Garza-Trevino ES, Overall JE, Hollister LE. Verapamil versus lithium in the treatment of acute mania. Am J  Psychiatry 1992; 149: 121-22.
  25. Kanba S, Yagi G, Kamijima K, et al. The first open study of zonisamide, a novel anticonvulsant, shows efficacy in mania. Progress Neuro-Psychopharmacol Biol Psychiat 1994; 18: 707-15.
  26. Mukherjee S, Sackheim HA, Schnur DB. Electroconvulsive therapy of acute manic episodes: a review of fifty years experience. Am J Psychiatry 1994; 151: 169-176.
  27. Grof P, Alda M, Grof E, et al. The challenge of predicting response to stabilising lithium treatment: the importance of patient selection. Br J Psychiatry 1993; 163 (suppl 21): 16-19.
  28. Goodwin GM. Recurrence of mania after lithium withdrawal. Br J Psychiatry 1994; 164: 149-52.
  29. Post RM, Leverich GS, Altshuler L, et al. Lithium discontinuation-induced refractoriness: preliminary observations. Am J Psychiatry 1992; 149: 1727-29.
  30. Jensen HV, Plenge P, Mellerup ET, et al. Lithium prophylaxis of manic-depressive disorder: daily lithium dosing schedule versus every second day. Acta Psychiatr Scand 1995; 1: 69-74.
  31. Faedda GL, Tondo L, Baldessarine RJ, et al. Outcomes after rapid versus gradual discontinuation of lithium treatment in bipolar disorders. Arch Gen Psychiatry 1993; 50: 448-58.
  32. Muller-Oerlinghausen B, Ahrens B, Groff E, et al. The effect of long-term lithium treatment on the mortality of patients with manic depressive and schizoaffective illness. Acta Psychiatr Scand 1992; 86: 218-22.
  33. White E, Cheung P, Silverstone T. Depot antipsychotics in bipolar affective disorder. Int Clin Psychopharmacol 1993; 8: 119-22.
  34. Scott J. Psychotherapy for bipolar disorder. Br J Psychiatry 1995; 167: 581-88


Top of Page